FrancophonIA/ELRC3.0 huggingface dataset:
English: In animal studies, peripheral administration of liraglutide led to uptake in specific brain regions involved in regulation of appetite, where liraglutide, via specific activation of the GLP1R, increased key satiety and decreased key hunger signals, thereby leading to lower body weight.
Croatian: U ispitivanjima na životinjama periferna primjena liraglutida rezultirala je unosom u određenim dijelovima mozga koji sudjeluju u regulaciji apetita, pri čemu je liraglutid putem specifične aktivacije GLP-1R povećao ključne signale sitosti i smanjio ključne signale gladi te time doveo do manje tjelesne težine.
English: Cumulative Frequency (%)
Croatian: Kumulativna učestalost (%)
English: FPG=fasting plasma glucose.
Croatian: FPG= glukoza u plazmi natašte.
English: It is similar to a natural occurring hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal.
Croatian: Sličan je prirodnom hormonu pod nazivom glukagonu sličan peptid-1 (GLP-1) koji se otpušta iz crijeva nakon obroka.
English: If you have diabetes, do not use Saxenda as a replacement for insulin.
Croatian: Ako imate šećernu bolest, nemojte primjenjivati lijek Saxenda kao zamjenu za inzulin.
English: Table 2 lists adverse reactions reported.
Croatian: U tablici 2 navode se prijavljene nuspojave.
English: Some patients may feel dizziness when taking Saxenda mainly during the first 3 months of treatment (see section ‘Possible side effects').
Croatian: Neki bolesnici mogu osjetiti omaglicu uglavnom u prva 3 mjeseca liječenja lijekom Saxenda (pogledajte dio „Moguće nuspojave“).
English: If it shows 3.0, at least 3.0 mg are left in your pen.
Croatian: Ako pokazuje 3,0, to znači da je najmanje 3,0 mg preostalo u brizgalici.
English: Only the dose counter and dose pointer will show how many mg you select per dose.
Croatian: Jedino će brojčanik doze i pokazivač doze pokazati koliko ste mg odabrali po dozi.
English: It must not be administered intravenously or intramuscularly.
Croatian: Ne smije se primjenjivati intravenski ili intramuskularno.
English: Usually, you will be told to follow the table below.
Croatian: Obično će Vam reći da se pridržavate tablice u nastavku.
English: From clinical trials and post-marketing use of liraglutide overdoses have been reported up to 72 mg (24 times the recommended dose for weight management).
Croatian: Iz kliničkih ispitivanja i nakon stavljanja liraglutida na tržište prijavljena su predoziranja dozama do 72 mg (24 puta veća doza od preporučene doze za kontrolu tjelesne težine).
English: The solution should not be used if it does not appear clear and colourless or almost colourless.
Croatian: Otopina se ne smije koristiti ako ne izgleda bistro i bezbojno ili gotovo bezbojno.
English: Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of
Croatian: Saxenda je indicirana kao dodatak dijeti sa smanjenim unosom kalorija i povećanoj fizičkoj aktivnosti za kontrolu tjelesne težine u odraslih bolesnika s početnim indeksom tjelesne mase (ITM) od
English: Liraglutide binds to and activates the GLP-1 receptor (GLP-1R).
Croatian: Liraglutid se veže na receptor GLP-1 (GLP-1R)
English: There is limited experience in patients with inflammatory bowel disease and diabetic gastroparesis.
Croatian: Iskustvo je ograničeno u bolesnika s upalnom bolešću crijeva i dijabetičkom gastroparezom.
English: Liraglutide exposure was not studied in patients with body weight >234 kg.
Croatian: Izloženost liraglutidu nije ispitivana u bolesnika tjelesne težine >234 kg.
English: You should only continue using Saxenda if you have lost at least 5% of your initial body weight after 12 weeks on the 3 mg/day dose (see section 3).
Croatian: Smijete nastaviti primjenjivati lijek Saxenda samo ako ste izgubili najmanje 5% početne tjelesne težine nakon 12 tjedana na dozi od 3 mg/dan (vidjeti dio 3.).
English: In vitro, liraglutide has shown very low potential to be involved in pharmacokinetic interactions with other active substances related to cytochrome P450 (CYP) and plasma protein binding.
Croatian: Liraglutid je in vitro pokazao vrlo nizak potencijal za stupanje u farmakokinetičke interakcije s drugim djelatnim tvarima koje se vežu na citokrom P450 (CYP) i na proteine plazme.
English: Upon initiation of liraglutide treatment in patients on warfarin or other coumarin derivatives, more frequent monitoring of International Normalised Ratio (INR) is recommended.
Croatian: Nakon uvođenja liječenja liraglutidom u bolesnika na varfarinu ili drugim kumarinskim derivatima, preporučuje se češće praćenje međunarodnog normaliziranog omjera (engl.
English: Patients with mild or moderate renal impairment (creatinine clearance ≥30 ml/min) may experience more gastrointestinal effects when treated with Saxenda.
Croatian: Bolesnici s blagim ili umjerenim oštećenjem bubrega (klirens kreatinina ≥30 ml/min ) mogu imati više gastrointestinalnih učinaka tijekom liječenja lijekom Saxenda.
English: Do not stop using Saxenda without talking to your doctor.
Croatian: Ako prestanete primjenjivati lijek Saxenda Nemojte prestati primjenjivati lijek Saxenda bez razgovora sa svojim liječnikom.
English: If escalation to the next dose step is not tolerated for two consecutive weeks, consider discontinuing treatment.
Croatian: Ako bolesnik ne podnosi povećanje na sljedeću dozu tijekom dva uzastopna tjedna, potrebno je razmotriti prekid liječenja.
English: • Injection site reactions (such as bruising, pain, irritation, itching and rash)
Croatian: • Reakcije na mjestu injiciranja (kao što su modrice, bol, nadraženost, svrbež i osip)
English: Saxenda pre-filled pen and needle (example)
Croatian: Saxenda napunjena brizgalica i igla (primjer)
English: If you have kidney disease or are on dialysis, consult your doctor.
Croatian: Ako imate bolest bubrega ili ste na dijalizi, posavjetujte se sa svojim liječnikom.
English: Patients should be informed of the characteristic symptoms of cholelithiasis and cholecystitis.
Croatian: Bolesnike je potrebno obavijestiti o karakterističnim simptomima kolelitijaze i kolecistitisa.
English: The risk of hypoglycaemia may be lowered by a reduction in the dose of insulin and/or sulfonylurea.
Croatian: Rizik od hipoglikemije može se smanjiti snižavanjem doze inzulina i/ili sulfonilureje.
English: If a drop still does not appear, dispose of the pen and use a new one.
Croatian: Ako se još uvijek ne pojavi kapljica, brizgalicu bacite u otpad i uzmite novu.
English: The starting dose is 0.6 mg once daily.
Croatian: Početna doza je 0,6 mg jednom dnevno.
English: The absorption of liraglutide following subcutaneous administration was slow, reaching maximum concentration approximately 11 hours post dosing.
Croatian: Nakon supkutane primjene apsorpcija liraglutida je spora i dostiže maksimalnu koncentraciju otprilike 11 sati nakon doziranja.
English: Pharmacokinetic properties were assessed in clinical pharmacology studies in the paediatric population with obesity aged 12-17 years (14 patients, body weight 80-122 kg) and 7-11 years (16 patients, body weight 45-87 kg) respectively.
Croatian: Farmakokinetička svojstva procjenjivala su se u farmakološkim kliničkim ispitivanjima u pretiloj pedijatrijskoj populaciji u dobi od 12 do 17 godina (14 bolesnika, tjelesne težine 80-122 kg) i u dobi od 7 do 11 godina (16 bolesnika, tjelesne težine 45-87 kg).
English: Liraglutide regulates appetite by increasing feelings of fullness and satiety, while lowering feelings of hunger and prospective food consumption, thereby leading to reduced food intake.
Croatian: Liraglutid regulira apetit pojačavanjem osjećaja punoće i sitosti te istodobnim ublažavanjem osjećaja gladi i potencijalne konzumacije hrane, što dovodi do smanjenog unosa hrane.
English: If the dose counter stops before 3.0 mg, there is not enough solution left for a full dose of 3.0 mg.
Croatian: Ako se brojčanik doze zaustavi prije 3,0 mg, to znači da nije ostalo dovoljno otopine za cijelu dozu od 3,0 mg.
English: It only shows approximately how much solution is left in your pen.
Croatian: Ona Vam samo pokazuje približno koliko je otopine preostalo u brizgalici.
English: If an anaphylactic reaction is suspected, liraglutide should be discontinued and treatment should not be restarted (see section 4.3).
Croatian: Ako se sumnja na anafilaktičku reakciju, liraglutid je potrebno ukinuti te se liječenje ne smije ponovo započeti (vidjeti dio 4.3).
English: • Do not use a double dose or increase the dose on the following day to make up for the missed dose.
Croatian: • Nemojte primijeniti dvostruku dozu niti povećati dozu sljedeći dan kako biste nadoknadili propuštenu dozu.
English: Saxenda should not be used in combination with another GLP-1 receptor agonist.
Croatian: Saxenda se ne smije upotrebljavati zajedno s drugim agonistom receptora GLP-1.
English: What Saxenda is and what it is used for What you need to know before you use Saxenda How to use Saxenda
Croatian: Što je Saxenda i za što se koristi Što morate znati prije nego počnete primjenjivati lijek Saxenda
English: Saxenda is supplied as a clear and colourless or almost colourless solution for injection in a pre-filled pen.
Croatian: Saxenda je bistra i bezbojna ili gotovo bezbojna otopina za injekciju u napunjenoj brizgalici.
English: A clinically relevant interaction with active substances with poor solubility or narrow therapeutic index such as warfarin cannot be excluded.
Croatian: Ne može se isključiti klinički značajna interakcija s djelatnim tvarima slabe topljivosti ili uskog terapijskog indeksa kao što je varfarin.
English: A majority of the reported events occurred in patients who had experienced nausea, vomiting or diarrhoea leading to volume depletion (see section 4.4).
Croatian: Većina prijavljenih događaja pojavila se u bolesnike kod kojih je bila prisutna mučnina, povraćanje ili proljev s posljedičnim smanjenjem volumena (vidjeti dio 4.4).
English: The hazard ratio and 95% CI is 0.33 [0.12; 0.90] for liraglutide versus placebo.
Croatian: Omjer hazarda i 95% CI iznosi 0,33 [0,12; 0,90] za liraglutid naspram placeba.
English: The fact that substantial weight loss can increase the risk of cholelithiasis and thereby cholecystitis only partially explained the higher rate with liraglutide.
Croatian: Činjenica da značajan gubitak tjelesne težine može povećati rizik od kolelitijaze i time kolecistitisa samo djelomično objašnjava višu stopu prilikom primjene liraglutida.
English: The majority of events were mild.
Croatian: Većina događaja bila je blagog intenziteta.
English: However, dizziness can be experienced mainly during the first 3 months of treatment with Saxenda.
Croatian: Međutim, može se osjetiti omaglica uglavnom u prva tri mjeseca liječenja lijekom Saxenda.
English: • Check that the solution in your pen is clear and colourless.
Croatian: • Provjerite da je otopina u brizgalici bistra i bezbojna.
English: When initiating Saxenda, it should be considered to reduce the dose of concomitantly administered insulin or insulin secretagogues (such as sulfonylureas) to reduce the risk of hypoglycaemia.
Croatian: Pri započinjanju liječenja lijekom Saxenda potrebno je razmotriti smanjivanje doze istodobno primijenjenog inzulina ili inzulinskih sekretagoga (kao što je sulfonilureja) kako bi se smanjio rizik od hipoglikemije.
English: The mean age was 64 years and the mean BMI was 32.5 kg/m².
Croatian: Srednja vrijednost dobi iznosila je 64 godine, a srednja vrijednost ITM-a bila je 32,5 kg/m².
English: • Do not mix Saxenda up with other medicines that you inject (e.g. insulins).
Croatian: • Nemojte miješati lijek Saxenda s drugim lijekovima koji se injiciraju (npr. inzulini).
English: Animal studies did not indicate direct harmful effects with respect to fertility but slightly increased early embryonic deaths at the highest dose.
Croatian: Ispitivanja na životinjama nisu ukazala na izravne štetne učinke na plodnost osim blago povećanog broja rane smrti embrija pri najvišoj dozi.
English: Diarrhoea may affect the absorption of concomitant oral medicinal products.
Croatian: Proljev može utjecati na apsorpciju istodobno uzetih oralnih lijekova.
English: Based on the results of population pharmacokinetic analysis, females have 24% lower weight adjusted clearance of liraglutide compared to males.
Croatian: Prema rezultatima populacijske farmakokinetičke analize žene imaju 24% niži klirens liraglutida prilagođen tjelesnoj težini u odnosu na muškarce.
English: Always use this medicine exactly as your doctor has told you.
Croatian: Kako primjenjivati lijek Saxenda Uvijek primijenite ovaj lijek točno onako kako Vam je rekao liječnik.
English: An extra dose or increase in dose should not be taken to make up for the missed dose.
Croatian: Ne smije se uzeti dodatna doza niti se doza smije povećati kako bi se nadoknadila propuštena doza.
English: Saxenda Placebo Last observation carried forward (LOCF)
Croatian: Saxenda Placebo Zadnje opažanje preneseno dalje
English: Antibody formation has not been associated with reduced efficacy of liraglutide.
Croatian: Stvaranje protutijela nije povezano sa smanjenom djelotvornošćui liraglutida.
English: Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) analogue with 97% amino acid sequence homology to endogenous human GLP-1.
Croatian: Liraglutid je acilirani analog humanog glukagonu sličnog peptida-1 (GLP-1) s podudarnošću sekvence aminokiselina od 97% s endogenim humanim GLP-1.
English: • Loss of fluids (dehydration).
Croatian: • Gubitak tekućine (dehidracija).
English: Treatment with liraglutide significantly improved systolic blood pressure and waist circumference compared with placebo (tables 3, 4 and 5).
Croatian: Liječenje liraglutidom značajno je poboljšalo sistolički krvni tlak i opseg struka u usporedbi s placebom (tablice 3, 4 i 5).
English: During 24 hours following administration of a single [3H]-liraglutide dose to healthy subjects, the major component in plasma was intact liraglutide.
Croatian: Tijekom 24 sata od primjene jedne doze [3H]-liraglutida u zdravih ispitanika glavna sastavnica u plazmi bio je nepromijenjeni liraglutid.
English: In the 56-week part of trial 1, 67.5% achieved ≥5% weight loss after 12 weeks.
Croatian: U 56-tjednom dijelu 1. ispitivanja 67,5% postiglo je smanjenje tjelesne težine ≥5% nakon 12 tjedana.
English: Saxenda is not recommended for use in paediatric patients.
Croatian: Pedijatrijska populacija Saxenda nije preporučena za primjenu u pedijatrijskih bolesnika.
English: Hypoglycaemia* Dehydration
Croatian: Hipoglikemija* Dehidracija
English: • Low blood sugar (hypoglycaemia).
Croatian: • Niska razina šećera u krvi (hipoglikemija).
English: Signs and symptoms of dehydration, including renal impairment and acute renal failure, have been reported in patients treated with GLP-1 receptor agonists.
Croatian: Znakovi i simptomi dehidracije, uključujući oštećenje bubrega i akutno zatajenje bubrega, prijavljeni su u bolesnika liječenih agonistima receptora GLP-1.
English: Cholelithiasis and cholecystitis
Croatian: Kolelitijaza i kolecistitis
English: This is because it is not known if Saxenda passes into breast milk.
Croatian: To je zato što nije poznato prelazi li Saxenda u majčino mlijeko.
English: A mean increase in heart rate from baseline of 2.5 beats per minute (ranging across trials from 1.6 to 3.6 beats per minute) has been observed with liraglutide in clinical phase 3 trials.
Croatian: Srednje povećanje srčane frekvencije u odnosu na početnu vrijednost od 2,5 otkucaja po minuti (u različitim ispitivanjima u rasponu od 1,6 do 3,6 otkucaja po minuti) zabilježeno je tijekom liječenja liraglutidom u kliničkim ispitivanjima faze 3.
English: The efficacy and safety of liraglutide for weight management in conjunction with reduced calorie intake and increased physical activity were studied in four phase 3 randomised, double-blind, placebocontrolled trials which included a total of 5,358 patients.
Croatian: Klinička djelotvornost i sigurnost Djelotvornost i sigurnost liraglutida za kontrolu tjelesne težine u kombinaciji s dijetom sa smanjenim unosom kalorija i povećanom fizičkom aktivnošću ispitane su u četiri randomizirana, dvostruko slijepa i placebom kontrolirana ispitivanja faze 3 koja su uključivala ukupno 5358 bolesnika.
English: • you are taking medicines for diabetes called ‘sulfonylurea' (such as glimepiride or glibenclamide) or if you are taking insulin - you may get low blood sugar (hypoglycaemia)
Croatian: • uzimate lijekove za liječenje šećerne bolesti pod nazivom „sulfonilureja” (kao što je glimepirid ili glibenklamid) ili ako primjenjujete inzulin - može Vam pasti razina šećera u krvi (hipoglikemija) ako koristite te lijekove zajedno s lijekom Saxenda.
English: The background treatment at trial start was either diet and exercise alone, metformin, a sulfonylurea, a glitazone as single agents or any combination hereof.
Croatian: Osnovno liječenje na početku ispitivanja uključivalo je ili samo dijetu i tjelovježbu, metformin, sulfonilureju i glitazon kao samostalne lijekove ili bilo koju njihovu kombinaciju.
English: In clinical trials, 2.5% of patients treated with liraglutide developed anti-liraglutide antibodies.
Croatian: U kliničkim ispitivanjima u 2,5% bolesnika liječenih liraglutidom razvila su se protutijela na liraglutid.
English: Patients treated with liraglutide should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion.
Croatian: Bolesnike liječene liraglutidom potrebno je upozoriti na mogući rizik od dehidracije zbog gastrointestinalnih nuspojava i na to da poduzmu mjere opreza kako bi izbjegli gubitak tekućine.
English: Interaction studies have been performed with 1.8 mg liraglutide.
Croatian: Ispitivanja interakcija provedena su s 1,8 mg liraglutida.
English: Treatment with liraglutide significantly improved glycaemic parameters across sub-populations with normoglycaemia, pre-diabetes and type 2 diabetes mellitus.
Croatian: Liječenje liraglutidom značajno je poboljšalo glikemijske parametre u svim podpopulacijama s normoglikemijom, predijabetesom i šećernom bolešću tipa 2.
English: Early responders were defined as patients who achieved ≥5% weight loss after 12 weeks on treatment dose of liraglutide (4 weeks of dose escalation and 12 weeks on treatment dose).
Croatian: Ispitanici s ranim odgovorom na liječenje definirani su kao bolesnici koji su postigli smanjenje tjelesne težine ≥5% nakon 12 tjedana na dozi liječenja liraglutidom (4 tjedna povećavanja doze i 12 tjedana na dozi liječenja).
English: Patients ≥65 years of age may experience more gastrointestinal effects when treated with Saxenda.
Croatian: ≥65 godina mogu imati više gastrointestinalnih učinaka tijekom liječenja lijekom
English: For patients who have achieved a weight loss of <5% after 12 weeks on treatment dose of liraglutide, the proportion of patients not reaching a weight loss of ≥10% after 1 year is 93.4%.
Croatian: U slučaju bolesnika koji su postigli smanjenje tjelesne težine <5% nakon 12 tjedana na dozi liječenja liraglutidom, udio bolesnika koji nisu postigli smanjenje tjelesne težine od ≥10% nakon jedne godine iznosi 93,4%.
English: When your pen contains less than 3.0 mg the dose counter stops before 3.0 is shown.
Croatian: Ako brizgalica sadrži manje od 3,0 mg, brojčanik doze zaustavlja se prije nego se prikaže 3,0.
English: Use of liraglutide is not recommended in these patients since it is associated with transient gastrointestinal adverse reactions, including nausea, vomiting and diarrhoea.
Croatian: Primjena liraglutida ne preporučuje se u tih bolesnika budući je povezana s prolaznim gastrointestinalnim nuspojavama uključujući mučninu, povraćanje i proljev.
English: Symptoms of hypoglycaemic events were reported by 1.6 % of patients treated with Saxenda and 1.1% of patients treated with placebo; however, these events were not confirmed by blood glucose measurements.
Croatian: Simptome hipoglikemijskih događaja prijavilo je 1,6% bolesnika liječenih lijekom Saxenda i 1,1% bolesnika koji su primali placebo; međutim, ti događaji nisu potvrđeni mjerenjima vrijednosti glukoze u krvi.
English: Overall, gastrointestinal reactions were the most frequently reported adverse reactions during treatment (67.9%) (see section ‘Description of selected adverse reactions').
Croatian: Sveukupno, najčešće prijavljene nuspojave tijekom liječenja lijekom Saxenda bile su gastrointestinalne nuspojave (67,9%) (vidjeti dio „Opis izdvojenih nuspojava”).
English: The mean clearance following subcutaneous administration of liraglutide is approximately 0.9-1.4 L/h with an elimination half-life of approximately 13 hours.
Croatian: Srednja vrijednost klirensa nakon supkutane primjene liraglutida iznosi otprilike 0,9-1,4 l/h, uz poluvijek eliminacije od otprilike 13 sati.
English: Diastolic blood pressure, mmHg
Croatian: Sistolički krvni tlak, mmHg Dijastolički krvni tlak, mmHg
English: Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Croatian: Drugi lijekovi i Saxenda Obavijestite svog liječnika, ljekarnika ili medicinsku sestru ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
English: The patient should be advised to discard the injection needle after each injection and store the pen without an injection needle attached.
Croatian: Bolesnika je potrebno savjetovati da nakon svakog injiciranja iglu za injiciranje baci u otpad, a brizgalicu spremi bez pričvršćene igle za injiciranje.
English: If there is less than 12 hours to the next dose, the patient should not take the missed dose and resume the once-daily regimen with the next scheduled dose.
Croatian: Ako je do sljedeće doze ostalo manje od 12 sati, bolesnik ne smije uzeti propuštenu dozu i sa sljedećom planiranom dozom treba nastaviti uobičajeni režim primjene jedanput na dan.
English: If you lose substantial weight, you are at a risk of gallstones and thereby inflamed gall bladder.
Croatian: Ako znatno izgubite na tjelesnoj težini, postoji rizik od žučnih kamenaca, a time i od upale žučnog mjehura.
English: When you are not using the pen, keep the pen cap on in order to protect it from light.
Croatian: Kad brizgalicu ne koristite, zatvorite je zatvaračem brizgalice radi zaštite od svjetlosti.
English: Liraglutide exposure was lowered by 33%, 14%, 27% and 26%, respectively, in patients with mild (creatinine clearance, CrCl 50-80 ml/min), moderate (CrCl 30-50 ml/min) and severe (CrCl <30 ml/min) renal impairment and in end-stage renal disease requiring dialysis.
Croatian: Izloženost liraglutidu bila je smanjena za 33%, 14%, 27% odnosno 26% u ispitanika s blagim (klirens kreatinina, CrCl 50-80 ml/min), umjerenim (CrCl 30-50 ml/min) i teškim (CrCl <30 ml/min) oštećenjem bubrega, odnosno u završnom stadiju bolesti bubrega kada je potrebna dijaliza.
English: If pancreatitis is suspected, liraglutide should be discontinued; if acute pancreatitis is confirmed, liraglutide should not be restarted.
Croatian: potrebno je prekinuti primjenu liraglutida; ako se potvrdi akutni pankreatitis, liječenje liraglutidom ne smije se ponovno započeti.
English: The liraglutide exposure in adolescents (age 12-17 years) was similar to that in adults with obesity.
Croatian: U adolescenata (u dobi od 12 do 17 godina) izloženost liraglutidu bila je slična kao i kod odraslih pretilih bolesnika.
English: Saxenda vs. placebo
Croatian: Saxenda naspram placeba
English: • When you first start using Saxenda, the starting dose is 0.6 mg once a day, for at least one week.
Croatian: • Kada prvi puta počnete primjenjivati lijek Saxenda, početna doza je 0,6 mg jednom dnevno,
English: Liraglutide lowers body weight in humans mainly through loss of fat mass with relative reductions in visceral fat being greater than for subcutaneous fat loss.
Croatian: Liraglutid snižava tjelesnu težinu u ljudi uglavnom kroz gubitak masnog tkiva i pritom su relativna smanjenja količine visceralnog masnog tkiva veća nego smanjenja količine potkožnog masnog tkiva.